<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">A Pronounced Inflammatory Activity Characterizes the Early Fracture Healing Phase in Immunologically Restricted Patients</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-03-08">8 March 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Paula</forename><surname>Hoff</surname></persName>
							<email>paula.hoff@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Rheumatology and Clinical Immunology</orgName>
								<orgName type="institution">Charité University Hospital</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">German Rheumatism Research Center (DRFZ)</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Department of Orthopedics</orgName>
								<orgName type="institution">Jena University Hospital</orgName>
								<address>
									<addrLine>Campus Eisenberg</addrLine>
									<postCode>07607</postCode>
									<settlement>Eisenberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<address>
									<postCode>10117</postCode>
									<settlement>Endokrinologikum Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Timo</forename><surname>Gaber</surname></persName>
							<email>gaber@drfz.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Rheumatology and Clinical Immunology</orgName>
								<orgName type="institution">Charité University Hospital</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">German Rheumatism Research Center (DRFZ)</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Berlin-Brandenburg Center for Regenerative Therapies (BCRT)</orgName>
								<address>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cindy</forename><surname>Strehl</surname></persName>
							<email>strehl@drfz.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Rheumatology and Clinical Immunology</orgName>
								<orgName type="institution">Charité University Hospital</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">German Rheumatism Research Center (DRFZ)</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Manuela</forename><surname>Jakstadt</surname></persName>
							<email>jakstadt@drfz.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Rheumatology and Clinical Immunology</orgName>
								<orgName type="institution">Charité University Hospital</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">German Rheumatism Research Center (DRFZ)</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Holger</forename><surname>Hoff</surname></persName>
							<email>holger.hoff@icloud.com</email>
						</author>
						<author>
							<persName><forename type="first">Katharina</forename><surname>Schmidt-Bleek</surname></persName>
							<email>katharina.schmidt-bleek@charite.de</email>
							<affiliation key="aff1">
								<orgName type="department">German Rheumatism Research Center (DRFZ)</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution" key="instit1">Julius Wolff Institute</orgName>
								<orgName type="institution" key="instit2">Charité University Hospital</orgName>
								<address>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Annemarie</forename><surname>Lang</surname></persName>
							<email>annemarie.lang@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Rheumatology and Clinical Immunology</orgName>
								<orgName type="institution">Charité University Hospital</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">German Rheumatism Research Center (DRFZ)</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">School for Regenerative Therapies (BSRT)</orgName>
								<address>
									<postCode>13353</postCode>
									<settlement>Berlin-Brandenburg, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eric</forename><surname>Röhner</surname></persName>
							<email>e.roehner@krankenhaus-eisenberg.de</email>
							<affiliation key="aff2">
								<orgName type="department">Department of Orthopedics</orgName>
								<orgName type="institution">Jena University Hospital</orgName>
								<address>
									<addrLine>Campus Eisenberg</addrLine>
									<postCode>07607</postCode>
									<settlement>Eisenberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dörte</forename><surname>Huscher</surname></persName>
							<email>huscher@drfz.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Rheumatology and Clinical Immunology</orgName>
								<orgName type="institution">Charité University Hospital</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">German Rheumatism Research Center (DRFZ)</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Georg</forename><surname>Matziolis</surname></persName>
							<email>g.matziolis@krankenhaus-eisenberg.de</email>
							<affiliation key="aff2">
								<orgName type="department">Department of Orthopedics</orgName>
								<orgName type="institution">Jena University Hospital</orgName>
								<address>
									<addrLine>Campus Eisenberg</addrLine>
									<postCode>07607</postCode>
									<settlement>Eisenberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gerd-Rüdiger</forename><surname>Burmester</surname></persName>
							<email>gerd.burmester@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Rheumatology and Clinical Immunology</orgName>
								<orgName type="institution">Charité University Hospital</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">German Rheumatism Research Center (DRFZ)</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gerhard</forename><surname>Schmidmaier</surname></persName>
							<email>gerhard.schmidmaier@med.uni-heidelberg.de</email>
							<affiliation key="aff7">
								<orgName type="department">Department of Orthopedics</orgName>
								<orgName type="institution">University Hospital Heidelberg</orgName>
								<address>
									<postCode>69118</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Carsten</forename><surname>Perka</surname></persName>
							<email>carsten.perka@charite.de</email>
							<affiliation key="aff4">
								<orgName type="department">Berlin-Brandenburg Center for Regenerative Therapies (BCRT)</orgName>
								<address>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department">Center for Musculoskeletal Surgery</orgName>
								<orgName type="institution">Charité University Hospital</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Georg</forename><forename type="middle">N</forename><surname>Duda</surname></persName>
							<email>georg.duda@charite.de</email>
							<affiliation key="aff4">
								<orgName type="department">Berlin-Brandenburg Center for Regenerative Therapies (BCRT)</orgName>
								<address>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution" key="instit1">Julius Wolff Institute</orgName>
								<orgName type="institution" key="instit2">Charité University Hospital</orgName>
								<address>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Frank</forename><surname>Buttgereit</surname></persName>
							<email>frank.buttgereit@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Rheumatology and Clinical Immunology</orgName>
								<orgName type="institution">Charité University Hospital</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">German Rheumatism Research Center (DRFZ)</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Berlin-Brandenburg Center for Regenerative Therapies (BCRT)</orgName>
								<address>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">A Pronounced Inflammatory Activity Characterizes the Early Fracture Healing Phase in Immunologically Restricted Patients</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-03-08">8 March 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">0E447271A0F620F89BC2A470D93C5855</idno>
					<idno type="DOI">10.3390/ijms18030583</idno>
					<note type="submission">Received: 5 December 2016; Accepted: 5 March 2017;</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:27+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>immunologically restricted patients</term>
					<term>fracture hematoma</term>
					<term>inflammation</term>
					<term>fracture healing</term>
					<term>bone healing</term>
					<term>cytokines</term>
					<term>immune cells</term>
					<term>chemokines</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Immunologically restricted patients such as those with autoimmune diseases or malignancies often suffer from delayed or insufficient fracture healing.</s><s>In human fracture hematomas and the surrounding bone marrow obtained from immunologically restricted patients, we analyzed the initial inflammatory phase on cellular and humoral level via flow cytometry and multiplex suspension array.</s><s>Compared with controls, we demonstrated higher numbers of immune cells like monocytes/macrophages, natural killer T (NKT) cells, and activated T helper cells within the fracture hematomas and/or the surrounding bone marrow.</s><s>Also, several pro-inflammatory cytokines such as Interleukin (IL)-6 and Tumor necrosis factor α (TNFα), chemokines (e.g., Eotaxin and RANTES), pro-angiogenic factors (e.g., IL-8 and Macrophage migration inhibitory factor: MIF), and regulatory cytokines (e.g., IL-10) were found at higher levels within the fracture hematomas and/or the surrounding bone marrow of immunologically restricted patients when compared to controls.</s><s>We conclude here that the inflammatory activity on cellular and humoral levels at fracture sites of immunologically restricted patients considerably exceeds that of control patients.</s><s>The initial inflammatory phase profoundly differs between these patient groups and is probably one of the reasons for prolonged or insufficient fracture healing often occurring within immunologically restricted patients.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Introduction</head><p><s>Patients suffering from disorders which impact their immune function often exhibit delayed or ineffective fracture healing <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref>, and sometimes even the development of pseudarthrosis <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref>.</s><s>Very heterogeneous circumstances are associated with restricted immune functions: inter alia autoimmune diseases, malignancies, diabetes mellitus, osteoporosis, and persons suffering from alcoholism, but also among the elderly <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref>.</s><s>The reasons for impaired fracture healing in these patients are not yet known in detail.</s><s>Fracture healing is a complex regenerative process generally starting with inflammation <ref type="bibr" target="#b9">[10]</ref>.</s><s>After a trauma which leads to a fracture, a hematoma is formed in the fracture gap.</s><s>This fracture hematoma represents the site of the initial inflammatory phase <ref type="bibr" target="#b10">[11]</ref>.</s><s>We characterized previously the initial inflammatory phase of control patients from the immunological point of view <ref type="bibr" target="#b11">[12]</ref>.</s><s>We could confirm the inflammatory nature of this initial phase both on RNA and protein levels showing high concentrations of pro-inflammatory cytokines such as IL-1β, Interferon (IFNγ or TNFα and chemokines like Monocyte chemotactic protein 1 (MCP-1), Interferon gamma-induced protein 10 (IP-10) and Regulated on activation, normal T cell expressed and secreted (RANTES) <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b12">13]</ref>.</s><s>Furthermore, we demonstrated that immune cells invade and become activated <ref type="bibr" target="#b11">[12]</ref>.</s><s>Very little is known about these initial processes of fracture healing in patients with restricted immune functions.</s><s>The heterogeneous group of immunologically restricted patients analyzed in this study is described in greater detail in the Section 4 "Materials and Methods" subheading Section 4.1 "Patients".</s><s>On the RNA level, a distinctly increased inflammation has already been described for immunologically restricted patients <ref type="bibr" target="#b13">[14]</ref>.</s><s>Furthermore, we have shown that immunologically restricted patients exhibit an inadequate response to bioenergetically adverse conditions like hypoxia which characterize the early milieu within the fracture gap <ref type="bibr" target="#b13">[14]</ref>.</s><s>Both enhanced inflammatory response and inadequate adaptation to hypoxia may lead to the decreased expression of Runt-related transcription factor 2 (RUNX-2) shown in the fracture hematomas of patients with restricted immune functions <ref type="bibr" target="#b13">[14]</ref>.</s><s>RUNX-2 is a transcription factor mediating osteogenesis <ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref>.</s></p><p><s>Apart from this information, our knowledge about the initial inflammatory phase of fracture healing in immunologically restricted patients is still scarce and incomplete.</s><s>This drove us to perform a detailed analysis of immune cell populations and pro-inflammatory and regulatory cytokines, chemokines, and factors regulating angiogenesis within fracture hematomas and the surrounding tissue in patients suffering from disorders concerning impact on immune functions.</s><s>These results were then compared to those of previously analyzed data on fracture hematomas obtained from control patients (patients lacking co-morbidities associated with delayed fracture healing) <ref type="bibr" target="#b11">[12]</ref>.</s><s>Here, to our knowledge, we give the first detailed immunological characterization of the fracture hematoma from immunologically restricted patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.">Fracture Hematomas of Immunologically Restricted Patients Comprise Higher Amounts of</head><p><s>Monocytes/Macrophages, Hematopoietic Stem and Progenitor Cells, as Well as NKT Cells, While Less Regulatory T Cells Are Present, and T Helper Cells Exhibit an Activated Phenotype Immune cell populations were analyzed within the fracture hematoma (FH) and the surrounding bone marrow (SBM) of immunologically restricted (IR) patients (dark grey) and compared to FH and SBM of controls (light grey); the gating strategy is presented in Supplemental Figure <ref type="figure" target="#fig_0">1</ref>.</s><s>The amounts of CD14+ monocytes/macrophages (as percentage of all leucocytes found in the fracture hematoma) and CD34+ hematopoietic stem and progenitor cells (as percentage of all mononuclear cells) were increased significantly within SBM IR (surrounding bone marrow of immunologically restricted patients) when compared to SBM of controls and numerically within the FH IR when compared to FH of controls (Figure <ref type="figure" target="#fig_1">1A,B</ref>).</s><s>It should be noted that the data for controls presented in Figure <ref type="figure" target="#fig_0">1</ref> and elsewhere in this manuscript were taken from our recent publication <ref type="bibr" target="#b11">[12]</ref>.</s><s>The amounts of CD3+CD56+ natural killer T (NKT) cells (as percentage of all lymphocytes) and activated CD45RA−CD25+CD3+CD4+ T helper cells (as percentage of all T helper cells) were increased significantly within SBM IR (SBM of immunologically restricted patients) when compared to SBM of controls and significantly within the FH IR when compared to FH of controls (Figure <ref type="figure" target="#fig_1">1C,D</ref>).</s><s>The number of activated CD45RA−CD25+CD3+CD4+ T helper cells (as percentage of all T helper cells) within the FH IF was significantly increased when compared to SBM IR.</s><s>The CD25+CD127−CD3+CD4+ regulatory T cells (as percentage of all T helper cells) were significantly decreased within SBM IR when compared to SBM, but were significantly increased within the FH IR when compared to SBM IR (Figure <ref type="figure" target="#fig_1">1E</ref>).</s><s>For the Mann-Whitney U test for independent groups, and Wilcoxon t-test for paired samples, statistically significant probability values of p &lt; 0.05 are indicated.</s><s>to SBM of controls and significantly within the FH IR when compared to FH of controls (Figure <ref type="figure" target="#fig_1">1C,D</ref>).</s></p><p><s>The number of activated CD45RA−CD25+CD3+CD4+ T helper cells (as percentage of all T helper cells) within the FH IF was significantly increased when compared to SBM IR.</s><s>The CD25+CD127−CD3+CD4+ regulatory T cells (as percentage of all T helper cells) were significantly decreased within SBM IR when compared to SBM, but were significantly increased within the FH IR when compared to SBM IR (Figure <ref type="figure" target="#fig_1">1E</ref>).</s><s>For the Mann-Whitney U test for independent groups, and Wilcoxon t-test for paired samples, statistically significant probability values of p &lt; 0.05 are indicated.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.">Fracture Hematomas and the Surrounding Bone Marrow of Immunologically Restricted Patients Exhibit Higher Concentrations of Pro-Inflammatory Cytokines When Compared to Controls</head><p><s>Pro-inflammatory cytokines were quantified within the FH and SBM of controls (data previously published in <ref type="bibr" target="#b11">[12]</ref>) and immunologically restricted (IR) patients.</s><s>The concentrations of IL-1β, IL-9, IFNγ, and TNFα were significantly increased in both SBM IR and FH IR when compared to SBM and FH of controls (Figure <ref type="figure" target="#fig_4">2A,C,E,F</ref>).</s><s>The amount of IL-6 was significantly increased within the FH IR when compared to FH (Figure <ref type="figure" target="#fig_4">2B</ref>).</s><s>The concentration of IL-12 was significantly increased within the SBM IR when compared to SBM (Figure <ref type="figure" target="#fig_4">2D</ref>).</s><s>The amounts of IL-9, IFNγ, and TNFα were significantly decreased within the FH IR when compared to the corresponding SBM IR (Figure <ref type="figure" target="#fig_4">2C,E,F</ref>).</s><s>Mann-Whitney U test for independent groups, Wilcoxon t-test for paired samples, statistically significant probability values of p &lt; 0.05 are indicated.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.">Fracture Hematomas and the Surrounding Bone Marrow of Immunologically Restricted Patients Exhibit Higher Concentrations of Pro-Inflammatory Cytokines When Compared to Controls</head><p><s>Pro-inflammatory cytokines were quantified within the FH and SBM of controls (data previously published in <ref type="bibr" target="#b11">[12]</ref>) and immunologically restricted (IR) patients.</s><s>The concentrations of IL-1β, IL-9, IFNγ, and TNFα were significantly increased in both SBM IR and FH IR when compared to SBM and FH of controls (Figure <ref type="figure" target="#fig_4">2A,C,E,F</ref>).</s><s>The amount of IL-6 was significantly increased within the FH IR when compared to FH (Figure <ref type="figure" target="#fig_4">2B</ref>).</s><s>The concentration of IL-12 was significantly increased within the SBM IR when compared to SBM (Figure <ref type="figure" target="#fig_4">2D</ref>).</s><s>The amounts of IL-9, IFNγ, and TNFα were significantly decreased within the FH IR when compared to the corresponding SBM IR (Figure <ref type="figure" target="#fig_4">2C,E,F</ref>).</s><s>Mann-Whitney U test for independent groups, Wilcoxon t-test for paired samples, statistically significant probability values of p &lt; 0.05 are indicated.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3.">Regulatory Cytokines Are Increased at Fracture Sites of Immunologically Restricted Patients When Compared to Controls</head><p><s>The concentration of IL-10 was significantly increased only within the SBM IR when compared to SBM (Figure <ref type="figure" target="#fig_7">3A</ref>), while the concentration of IL-13 was significantly increased in both SBM IR and FH IR when compared to SBM and FH of controls (Figure <ref type="figure" target="#fig_7">3B</ref>).</s><s>For the Mann-Whitney U test for independent groups, and Wilcoxon t-test for paired samples, statistically significant probability values of p &lt; 0.05 are indicated.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3.">Regulatory Cytokines Are Increased at Fracture Sites of Immunologically Restricted Patients When Compared to Controls</head><p><s>The concentration of IL-10 was significantly increased only within the SBM IR when compared to SBM (Figure <ref type="figure" target="#fig_7">3A</ref>), while the concentration of IL-13 was significantly increased in both SBM IR and FH IR when compared to SBM and FH of controls (Figure <ref type="figure" target="#fig_7">3B</ref>).</s><s>For the Mann-Whitney U test for independent groups, and Wilcoxon t-test for paired samples, statistically significant probability values of p &lt; 0.05 are indicated.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3.">Regulatory Cytokines Are Increased at Fracture Sites of Immunologically Restricted Patients When Compared to Controls</head><p><s>The concentration of IL-10 was significantly increased only within the SBM IR when compared to SBM (Figure <ref type="figure" target="#fig_7">3A</ref>), while the concentration of IL-13 was significantly increased in both SBM IR and FH IR when compared to SBM and FH of controls (Figure <ref type="figure" target="#fig_7">3B</ref>).</s><s>For the Mann-Whitney U test for independent groups, and Wilcoxon t-test for paired samples, statistically significant probability values of p &lt; 0.05 are indicated.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4.">Fracture Hematomas and the Surrounding Bone Marrow of Immunologically Restricted Patients Exhibit Higher Concentrations of Chemokines When Compared to Controls</head><p><s>Chemokines were quantified within FH and SBM of controls <ref type="bibr" target="#b11">[12]</ref> and immunologically restricted (IR) patients.</s><s>The concentration of Eotaxin was significantly increased in both SBM IR and FH IR when compared to SBM and FH of controls (Figure <ref type="figure" target="#fig_9">4A</ref>).</s><s>The concentrations of IP-10 and RANTES were significantly increased within the SBM IR when compared to SBM (Figure <ref type="figure" target="#fig_9">4B,D</ref>).</s><s>The amount of Macrophage inflammatory protein 1α (MIP-1α) was significantly increased within the FH IR when compared to FH (Figure <ref type="figure" target="#fig_9">4C</ref>).</s><s>The MIP-1α concentration was significantly increased within the SBM IR when compared to the corresponding FH IR (Figure <ref type="figure" target="#fig_9">4C</ref>).</s><s>For the Mann-Whitney U test for independent groups, and Wilcoxon t-test for paired samples, statistically significant probability values of p &lt; 0.05 are indicated.</s></p><p><s>Int. J. Mol.</s><s>Sci.</s><s>2017, 18, 583 5 of 12</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4.">Fracture Hematomas and the Surrounding Bone Marrow of Immunologically Restricted Patients Exhibit Higher Concentrations of Chemokines When Compared to Controls</head><p><s>Chemokines were quantified within FH and SBM of controls <ref type="bibr" target="#b11">[12]</ref> and immunologically restricted (IR) patients.</s><s>The concentration of Eotaxin was significantly increased in both SBM IR and FH IR when compared to SBM and FH of controls (Figure <ref type="figure" target="#fig_9">4A</ref>).</s><s>The concentrations of IP-10 and RANTES were significantly increased within the SBM IR when compared to SBM (Figure <ref type="figure" target="#fig_9">4B,D</ref>).</s><s>The amount of Macrophage inflammatory protein 1α (MIP-1α) was significantly increased within the FH IR when compared to FH (Figure <ref type="figure" target="#fig_9">4C</ref>).</s><s>The MIP-1α concentration was significantly increased within the SBM IR when compared to the corresponding FH IR (Figure <ref type="figure" target="#fig_9">4C</ref>).</s><s>For the Mann-Whitney U test for independent groups, and Wilcoxon t-test for paired samples, statistically significant probability values of p &lt; 0.05 are indicated.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.5.">Factors Mediating Angiogenesis Were Found at Higher Concentrations within the Fracture Hematomas and the Surrounding Bone Marrow of Immunologically Restricted Patients When Compared to Controls</head><p><s>Angiogenic factors were quantified within the FH and SBM of controls <ref type="bibr" target="#b11">[12]</ref> and immunologically restricted (IR) patients.</s><s>The concentrations of IL-8, Platelet-derived growth factor (PDGF), and Granulocyte-colony stimulating factor (G-CSF) were significantly increased in SBM IR when compared to SBM of controls (Figure <ref type="figure" target="#fig_12">5A,C,D</ref>).</s><s>The amount of MIF was significantly increased within the FH IR when compared to FH (Figure <ref type="figure" target="#fig_12">5B</ref>).</s><s>The IL-8 and MIF concentrations were significantly increased within the FH IR when compared to the corresponding SBM IR (Figure <ref type="figure" target="#fig_12">5A,B</ref>).</s><s>For the  Angiogenic factors were quantified within the FH and SBM of controls <ref type="bibr" target="#b11">[12]</ref> and immunologically restricted (IR) patients.</s><s>The concentrations of IL-8, Platelet-derived growth factor (PDGF), and Granulocyte-colony stimulating factor (G-CSF) were significantly increased in SBM IR when compared to SBM of controls (Figure <ref type="figure" target="#fig_12">5A,C,D</ref>).</s><s>The amount of MIF was significantly increased within the FH IR when compared to FH (Figure <ref type="figure" target="#fig_12">5B</ref>).</s><s>The IL-8 and MIF concentrations were significantly increased within the FH IR when compared to the corresponding SBM IR (Figure <ref type="figure" target="#fig_12">5A,B</ref>).</s><s>For the Mann-Whitney U test for independent groups, and Wilcoxon t-test for paired samples, statistically significant probability values of p &lt; 0.05 are indicated.</s></p><p><s>Mann-Whitney U test for independent groups, and Wilcoxon t-test for paired samples, statistically significant probability values of p &lt; 0.05 are indicated.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Discussion</head><p><s>The initial inflammatory phase of fracture healing differs between controls and immunologically restricted patients.</s><s>As we have shown before, in controls (patients lacking co-morbidities associated with delayed fracture healing) there is significant inflammatory activity within the fracture hematoma (FH) and surrounding bone marrow (SBM) <ref type="bibr" target="#b11">[12]</ref>.</s><s>This situation was seen to be different to that found in immunologically restricted patients who are known to suffer more often from delayed or insufficient fracture healing <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref>, as shown in this work here.</s><s>Previously, we could demonstrate pronounced inflammation and inadequate response to hypoxia in fracture hematomas of immunologically restricted patients on the RNA level <ref type="bibr" target="#b13">[14]</ref>.</s><s>Here we confirm these data on the protein level and add detailed information by extensively characterizing cellular composition, cellular activity, and cytokine/chemokine milieu.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.">Immune Cells in Fracture Hematoma of Immunologically Restricted Patients</head><p><s>We observed an increased invasion of monocytes/macrophages into the SBM of IR patients when compared to controls.</s><s>It is well known that macrophages invade the fracture site and are essential for bone regeneration <ref type="bibr" target="#b17">[18]</ref>.</s><s>The higher number of them found in the IR-group is probably due to increased concentrations of chemokines like MIP-1α and RANTES (CCL3/5) which facilitate the immigration of monocytes/macrophages <ref type="bibr" target="#b18">[19]</ref>.</s><s>The overall increased inflammatory level within FH and SBM obtained from immunologically restricted patients presumably also leads to the high numbers observed for hematopoietic stem and progenitor cells, as well as NKT cells.</s><s>The</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Discussion</head><p><s>The initial inflammatory phase of fracture healing differs between controls and immunologically restricted patients.</s><s>As we have shown before, in controls (patients lacking co-morbidities associated with delayed fracture healing) there is significant inflammatory activity within the fracture hematoma (FH) and surrounding bone marrow (SBM) <ref type="bibr" target="#b11">[12]</ref>.</s><s>This situation was seen to be different to that found in immunologically restricted patients who are known to suffer more often from delayed or insufficient fracture healing <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref>, as shown in this work here.</s><s>Previously, we could demonstrate pronounced inflammation and inadequate response to hypoxia in fracture hematomas of immunologically restricted patients on the RNA level <ref type="bibr" target="#b13">[14]</ref>.</s><s>Here we confirm these data on the protein level and add detailed information by extensively characterizing cellular composition, cellular activity, and cytokine/chemokine milieu.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.">Immune Cells in Fracture Hematoma of Immunologically Restricted Patients</head><p><s>We observed an increased invasion of monocytes/macrophages into the SBM of IR patients when compared to controls.</s><s>It is well known that macrophages invade the fracture site and are essential for bone regeneration <ref type="bibr" target="#b17">[18]</ref>.</s><s>The higher number of them found in the IR-group is probably due to increased concentrations of chemokines like MIP-1α and RANTES (CCL3/5) which facilitate the immigration of monocytes/macrophages <ref type="bibr" target="#b18">[19]</ref>.</s><s>The overall increased inflammatory level within FH and SBM obtained from immunologically restricted patients presumably also leads to the high numbers observed for hematopoietic stem and progenitor cells, as well as NKT cells.</s><s>The concentration of Eotaxin (CCL11) is high which could be responsible for the high number of CD34+ hematopoietic stem and progenitor cells (HSPC) which we saw <ref type="bibr" target="#b19">[20]</ref>.</s><s>In turn, monocytes, NKT cells but also HSPC become activated, proliferate, and then contribute to the inflammation via production of cytokines/chemokines.</s><s>We could clearly demonstrate that the pronounced inflammatory situation within the fracture site in IR-patients leads to the activation of T helper cells as evidenced by the fact that CD25 is up-regulated, and CD45RA is down-regulated in this population.</s><s>One possible explanation might be the relative lack of regulatory T cells as we could show lower numbers of CD25+CD127− regulatory T cells especially within the SBM of IR patients when compared to controls.</s><s>We previously showed the activation of cytotoxic T cells at fracture sites in control patients <ref type="bibr" target="#b11">[12]</ref>.</s><s>Within the IR-group it seems to be the T helper cells which are being significantly more activated.</s><s>This facilitates the production of pro-inflammatory cytokines, and we found these at higher concentrations within FH/SBM of the immunologically restricted patients when compared to controls.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.">Pro-Inflammatory and Regulatory Cytokines at the Fracture Site of Immunologically Restricted Patients</head><p><s>Also the concentration of IL-1β was significantly higher within the FH and SBM of immunologically restricted patients when compared to the controls.</s><s>On the one hand, IL-1β contributes to the proliferation of osteoblasts and thus to bone regeneration <ref type="bibr" target="#b20">[21,</ref><ref type="bibr" target="#b21">22]</ref>, but on the other hand, a long exposure to IL-1β inhibits osteoblast migration and contributes to delayed healing <ref type="bibr" target="#b22">[23]</ref>.</s><s>We showed higher numbers of macrophages in the IR group which could be the source for the significantly increased concentrations of IL-6 and TNFα.</s><s>IL-6 and TNFα together with the increased concentration of IL-1β could trigger increased osteoclastogenesis leading to increased resorption <ref type="bibr" target="#b23">[24]</ref>.</s></p><p><s>T helper cells (activated at fracture sites of IR-patients) produce IL-9 which is found at significantly higher concentrations in the IR-patients compared to controls, and this could lead to the observed higher number of hematopoietic stem and progenitor cells <ref type="bibr" target="#b24">[25]</ref>.</s><s>Mice lacking IL-12 and IL-23 show increased bone formation <ref type="bibr" target="#b25">[26]</ref>.</s><s>We demonstrated significantly higher concentrations of IL-12 within the immunologically restricted patients than those seen in the controls.</s><s>IL-12 stimulates T helper cells to produce IFNγ which we have also shown to be significantly increased within the IR-patients.</s><s>In turn, high IFNγ can inhibit the differentiation of mesenchymal stem cells and thus contribute to impaired fracture healing <ref type="bibr" target="#b25">[26]</ref>.</s><s>Mesenchymal stem cells are essential for fracture healing <ref type="bibr" target="#b26">[27]</ref>.</s><s>They migrate to the fracture site and are important progenitors of osteoblasts and bone lining cells <ref type="bibr" target="#b27">[28]</ref>.</s><s>However, they are also assumed to contribute to the termination of the initial inflammation in fracture healing via their immunomodulatory properties such as the secretion of IL-10 <ref type="bibr" target="#b28">[29]</ref>.</s><s>Thus, the significantly increased concentration of IL-10 could point to the higher activity of mesenchymal stem cells which might attempt to counter-regulate the profound inflammation in IR-patients.</s><s>IL-13 is a regulatory cytokine closely related to IL-4 <ref type="bibr" target="#b29">[30]</ref>.</s><s>Activated T cells like those which we have shown to be present at fracture sites do secrete IL-13 and modulate monocyte and B cell function through IL-13 for example via the suppression of pro-inflammatory cytokine production <ref type="bibr" target="#b29">[30,</ref><ref type="bibr" target="#b30">31]</ref>.</s><s>At the fracture site we showed a significantly increased concentration of IL-13 which might be secreted in order to counter-regulate the elevated inflammation in the IR-patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.">Chemokines at Fracture Sites of Immunologically Restricted Patients</head><p><s>We showed an accumulation of monocytes/macrophages, NKT cells and activated T helper cells at fracture sites in immunologically restricted patients in comparison with the controls.</s><s>These cells are able to secrete diverse chemokines but are also factors regulating vascularization <ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref>.</s><s>Furthermore, the significantly increased concentration of Eotaxin probably explains the accumulation of CD34+ hematopoietic stem and progenitor cells within the immunologically restricted patients <ref type="bibr" target="#b19">[20]</ref>.</s><s>IP-10 might be up-regulated as a consequence of the increased concentration of IFNγ <ref type="bibr" target="#b35">[36]</ref>.</s><s>The increased amount of MIP-1α might contribute to disturbed osteoblast function, as MIP-1α is able to inhibit osteoblast differentiation <ref type="bibr" target="#b36">[37]</ref>.</s><s>RANTES is an important chemokine in bone homeostasis.</s><s>It promotes chemo-attraction of osteoblasts and osteoblast survival <ref type="bibr" target="#b37">[38]</ref>.</s><s>Thus, RANTES is certainly important for bone regeneration and we also showed that secretion of RANTES in FH and SBM is present in the controls <ref type="bibr" target="#b11">[12]</ref>.</s><s>However, it is also osteoclasts which express the RANTES receptor CCR1 and thus the very high amount of RANTES might contribute to insufficient fracture healing in the immunologically restricted patients <ref type="bibr" target="#b37">[38]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4.">Angiogenic Factors in Fracture Hematomas of Immunologically Restricted Patients</head><p><s>The pronounced inflammatory activity within the FH/SBM of immunologically restricted patients is a high energy-consuming process <ref type="bibr" target="#b38">[39]</ref>.</s><s>Thus, the demand for revascularization is huge.</s><s>Vascularization of course is essential for bone regeneration <ref type="bibr" target="#b39">[40,</ref><ref type="bibr" target="#b40">41]</ref>.</s><s>As we have shown before, there are high concentrations of factors mediating angiogenesis present at fracture sites of controls <ref type="bibr" target="#b11">[12]</ref>.</s><s>However, the pronounced inflammation within the immunologically restricted group might lead to an even significantly higher production of pro-angiogenic factors in IR-patients as we showed for IL-8, MIF, PDGF, and G-CSF.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Materials and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.">Patients</head><p><s>We analyzed patients with closed fractures undergoing a surgery within 72 h post injury.</s><s>All patients gave their written informed consent.</s><s>The local ethical committee approved the study.</s></p><p><s>Patients meeting the inclusion and exclusion criteria summarized in Table <ref type="table" target="#tab_1">1</ref> were defined as controls (n = 42) <ref type="bibr" target="#b11">[12]</ref>.</s><s>Patients with autoimmune diseases, cancer, diabetes mellitus, osteoporosis, or alcoholism were defined as immunologically restricted patients (n = 20) (see Table <ref type="table">2</ref>).</s><s>These risk factors are known to be associated with prolonged or ineffective fracture healing <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b41">[42]</ref><ref type="bibr" target="#b42">[43]</ref><ref type="bibr" target="#b43">[44]</ref><ref type="bibr" target="#b44">[45]</ref>.</s><s>Patients with the following autoimmune diseases were included: rheumatoid arthritis, cryoglobulinemic vasculitis, systemic lupus erythematosus, and giant cell arteritis.</s><s>Patients with the following cancer diseases were included: non-Hodgkin lymphoma, 2 mamma carcinoma, and bronchial carcinoma.</s></p><p><s>Table <ref type="table">2</ref>. Inclusion and exclusion criteria for patients defined as immunologically restricted patients, the number of patients matching the inclusion criteria is given.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Inclusion Criteria</head><p><s>Exclusion The patient characteristics are given in Table <ref type="table" target="#tab_2">3</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.">Tissue Samples</head><p><s>Fracture hematoma (FH) and bone marrow surrounding the fracture hematoma (surrounding bone marrow, SBM): FH and SBM were obtained from patients (controls and immunologically restricted patients) with a closed fracture undergoing an osteosynthesis &lt;72 h after fracture.</s><s>The samples were kept in heparinized tubes to prevent coagulation of the SBM (Figure <ref type="figure" target="#fig_1">S1A</ref>), the FH was already coagulated when removed ex vivo.</s><s>Thus, FH and SBM could be separated via filtration of the liquid SBM (70 µm cell strainer, BD Biosciences, Heidelberg, Germany) (Figure <ref type="figure" target="#fig_1">S1B</ref>) as described previously <ref type="bibr" target="#b11">[12]</ref>.</s><s>After separation of FH and SBM the coagulated FH was pressed through the cell strainer to prepare single cells (Figure <ref type="figure" target="#fig_1">S1C</ref>).</s><s>All samples were centrifuged to separate cells and supernatant (Figure <ref type="figure" target="#fig_1">S1D</ref>).</s><s>The cell-free supernatant was used for cytokine/chemokine analysis.</s><s>The cell pellet was used for cytometric analysis.</s></p><p><s>Erythrocyte lysis was performed with cell pellets for 6 min at 4 • C (erythrocyte lysis buffer: 0.01 M KHCO 3 , 0.155 M NH 4 Cl, 0.1mM EDTA, pH 7.5).</s><s>The samples were washed with phosphate buffered saline supplemented with 0.5% (w/v) bovine serum albumin (137 mM NaCl + 2.7 mM KCl + 1.5 mM KH 2 PO 4 + 7.9 mM Na 2 HPO4•xH 2 O, pH 7.2 + 30 mM bovine serum albumin).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3.">Flow Cytometry</head><p><s>Leukocytes were filtered (MACS pre-separation filter 30 µm, Miltenyi Biotech, Bergisch Gladbach, Germany) and incubated in a solution containing 5 mg/mL human IgG (IgG1 66.6%, IgG2 28.5%, IgG3 2.7% &amp; IgG4 2.2%; Flebogamma, Grifols, Frankfurt, Germany) to block unspecific binding.</s><s>Cells were stained with for 10 min at 4 • C with αCD3 (UCHT1), αCD56 (B159), αCD127 (hIL-7R-M21), αCCR7 (3D12), αCD4 (RPA-T4), αCD25 (M-A251), αCD19 (HIB19), αCD34 (581), αCD14 (M5E2), αCD16 (3G8), αCD69 (FN50), αIgD (IA6-2) (all from BD Biosciences, Heidelberg, Germany); αCD45RA (MEM-56) and αCD8 (3B5) (both from Caltag Laboratories, Hamburg, Germany) conjugated to Pacific blue, Pacific orange, PE-Cy7, PE, PE-Cy5, APC, APC-Cy7, APC-Alexa750 or FITC.</s><s>Analysis was performed using a LSR II cytometer (BD Biosciences, Heidelberg, Germany) and FlowJo software (Tree Star, Ashland, OR, USA).</s><s>Significantly different populations were presented when compared controls and immunologically restricted patients.</s><s>Gating strategy is presented in Figure <ref type="figure" target="#fig_4">S2</ref>: granulocytes were defined according to scatter and via CD16 expression.</s><s>Monocytes and macrophages were analyzed in scatter and via CD14 expression.</s><s>Lymphocytes subpopulations were analyzed via expression of CD3, CD4, CD8, CD19, CD56, and their combinations.</s><s>The activation and further differentiation was analyzed via the expression of CD25, CD69, CD45RA, CCR7, CD127, IgD.</s><s>Only those results significantly different between controls and IR-patients are presented.</s><s>Hematopoietic stem and progenitor cells were analyzed via the expression of CD34 within the mononuclear cell population defined in the scatter dot plot</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.4.">Cytokines, Chemokines and Growth Factors</head><p><s>The concentrations of cytokines, chemokines and growth factors were measured by a Bioplex system (Bio-Rad Laboratories, Munich, Germany) according to the manufacturer's instructions.</s><s>The following cytokines and chemokines were quantified: interleukin (IL)-1β, IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-13, IL-15, IL-17, interferon-gamma (IFNγ), interferon-gamma-induced protein 10 (CXCL10, IP-10), tumor necrosis factor-alpha (TNFα), IL-1 receptor antagonist (IL-1ra), IL-4, IL-10, monocyte chemotactic protein-1 (MCP-1, CCL2), macrophage inflammatory protein 1α (MIP-1α, CCL3), MIP-1β (CCL4), Eotaxin (CCL11), basic fibroblast growth factor (FGF basic), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), CCL5 (regulated on activation normal T-cell expressed and secreted, RANTES), and MIF (macrophage migration inhibitory factor).</s><s>Significantly different concentrations were presented when controls' and immunologically restricted patients' values were compared.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.5.">Statistical Analysis</head><p><s>Statistical tests were performed using Graph Pad Prism Software (Graph Pad, San Diego, CA, USA).</s><s>Data are shown as box and whiskers using the Tukey method.</s><s>Intra-individual differences between FH and the corresponding SBM were analyzed using the Wilcoxon t-test for paired samples.</s><s>The differences between different patients groups (controls and immunologically restricted patients) were analyzed using the Mann-Whitney U test for independent groups.</s><s>Probability values of p &lt; 0.05 were considered to be statistically significant; the p-values are presented within the Figures.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">Conclusions</head><p><s>There is a pronounced inflammatory activity on cellular and humoral levels at the fracture site of immunologically restricted patients which significantly exceeds the normal inflammatory level of controls (Figure <ref type="figure" target="#fig_14">6</ref>).</s><s>The initial inflammatory phase differs between these patients and is probably one of the reasons for the prolonged or insufficient fracture healing often occurring within immunologically restricted patients.</s></p><p><s>Int. J. Mol.</s><s>Sci.</s><s>2017, 18, 583 10 of 12 granulocyte macrophage colony-stimulating factor (GM-CSF), CCL5 (regulated on activation normal T-cell expressed and secreted, RANTES), and MIF (macrophage migration inhibitory factor).</s><s>Significantly different concentrations were presented when controls' and immunologically restricted patients' values were compared.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.5.">Statistical Analysis</head><p><s>Statistical tests were performed using Graph Pad Prism Software (Graph Pad, San Diego, CA, USA).</s><s>Data are shown as box and whiskers using the Tukey method.</s><s>Intra-individual differences between FH and the corresponding SBM were analyzed using the Wilcoxon t-test for paired samples.</s><s>The differences between different patients groups (controls and immunologically restricted patients) were analyzed using the Mann-Whitney U test for independent groups.</s><s>Probability values of p &lt; 0.05 were considered to be statistically significant; the p-values are presented within the Figures.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">Conclusions</head><p><s>There is a pronounced inflammatory activity on cellular and humoral levels at the fracture site of immunologically restricted patients which significantly exceeds the normal inflammatory level of controls (Figure <ref type="figure" target="#fig_14">6</ref>).</s><s>The initial inflammatory phase differs between these patients and is probably one of the reasons for the prolonged or insufficient fracture healing often occurring within immunologically restricted patients.</s><s>Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/3/583/s1.</s></p><p><s>Acknowledgments: This study was supported by the German Research Foundation (DFG Bu1015/6-1).</s></p><p><s>Author Contributions: Paula Hoff, Timo Gaber, Georg Matziolis, Gerd-Rüdiger Burmester, Cindy Strehl,</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Monocytes/macrophages, hematopoietic stem and progenitor cells, natural killer T (NKT) cells and activated T helper cells accumulate in fracture hematoma (FH)/surrounding bone marrow (SBM) of immunologically restricted (FH IR/SBM IR) patients while regulatory T cells are decreased in SBM.</s><s>Leukocytes from FH IR/SBM IR of immunologically restricted patients (dark grey) and controls (light grey) were isolated, stained with various surface markers and analyzed by flow cytometry.</s><s>(A) Within all leukocytes, the CD14+ monocytes/macrophages were detected; (B) CD34+ hematopoietic stem and progenitor cells were detected within the mononuclear cells; (C) CD3+CD56+ NKT cells were detected within lymphocytes; (D) The activated CD45RA−CD25+CD3+CD4+ T helper cells were detected within the whole T helper cell population; (E) CD25+CD127−CD3+CD4+ regulatory T cells were detected within the whole T helper cell population.</s><s>Controls n = 42, IR patients n = 20.</s><s>IR-patients vs. controls Mann-Whitney U test, FH vs. corresponding SBM Wilcoxon test, p-values &lt; 0.05 are shown as numbers in the Figure.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Monocytes/macrophages, hematopoietic stem and progenitor cells, natural killer T (NKT) cells and activated T helper cells accumulate in fracture hematoma (FH)/surrounding bone marrow (SBM) of immunologically restricted (FH IR/SBM IR) patients while regulatory T cells are decreased in SBM.</s><s>Leukocytes from FH IR/SBM IR of immunologically restricted patients (dark grey) and controls (light grey) were isolated, stained with various surface markers and analyzed by flow cytometry.</s><s>(A) Within all leukocytes, the CD14+ monocytes/macrophages were detected; (B) CD34+ hematopoietic stem and progenitor cells were detected within the mononuclear cells; (C) CD3+CD56+ NKT cells were detected within lymphocytes; (D) The activated CD45RA−CD25+CD3+CD4+ T helper cells were detected within the whole T helper cell population; (E) CD25+CD127−CD3+CD4+ regulatory T cells were detected within the whole T helper cell population.</s><s>Controls n = 42, IR patients n = 20.</s><s>IR-patients vs. controls Mann-Whitney U test, FH vs. corresponding SBM Wilcoxon test, p-values &lt; 0.05 are shown as numbers in the Figure.</s></p></div></figDesc><graphic coords="3,140.43,221.65,313.75,186.96" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Pro-inflammatory cytokines are found at high concentrations in FH/SBM of immunologically restricted patients (FH IR/SBM IR).</s><s>Supernatants from FH and SBM of immunologically restricted patients (FH IR/SBM IR: dark grey) and controls (FH/SBM: light grey) were analyzed for the concentrations of pro-inflammatory cytokines via multiplex suspension array.</s><s>(A) Interleukin (IL)-1β; (B) IL-6; (C) IL-9; (D) IL-12; (E) Interferon γ (IFN)γ; (F) Tumor necrosis factor α (TNFα).</s><s>Controls n = 42, IR patients n = 20.</s><s>IR-patients vs. controls Mann-Whitney U test, FH vs. corresponding SBM Wilcoxon test, p-values &lt; 0.05 are shown as numbers in the Figure.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 3 .</head><label>3</label><figDesc><div><p><s>Figure 3. Regulatory cytokines are increased in FH/SBM of immunologically restricted patients.</s><s>Supernatants from FH and SBM of immunologically restricted patients (FH IR/SBM IR: dark grey) and controls (FH/SBM: light grey) were analyzed for the concentrations of regulatory cytokines via multiplex suspension array.</s><s>(A) IL-10; (B) IL-13.</s><s>Controls n = 42, IR patients n = 20.</s><s>IR-patients vs. controls Mann-Whitney U test, FH vs. corresponding SBM Wilcoxon test, p-values &lt; 0.05 are shown as numbers in the Figure.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Pro-inflammatory cytokines are found at high concentrations in FH/SBM of immunologically restricted patients (FH IR/SBM IR).</s><s>Supernatants from FH and SBM of immunologically restricted patients (FH IR/SBM IR: dark grey) and controls (FH/SBM: light grey) were analyzed for the concentrations of pro-inflammatory cytokines via multiplex suspension array.</s><s>(A) Interleukin (IL)-1β; (B) IL-6; (C) IL-9; (D) IL-12; (E) Interferon γ (IFN)γ; (F) Tumor necrosis factor α (TNFα).</s><s>Controls n = 42, IR patients n = 20.</s><s>IR-patients vs. controls Mann-Whitney U test, FH vs. corresponding SBM Wilcoxon test, p-values &lt; 0.05 are shown as numbers in the Figure.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>12 Figure 2 .</head><label>122</label><figDesc><div><p><s>Figure 2. Pro-inflammatory cytokines are found at high concentrations in FH/SBM of immunologically restricted patients (FH IR/SBM IR).</s><s>Supernatants from FH and SBM of immunologically restricted patients (FH IR/SBM IR: dark grey) and controls (FH/SBM: light grey) were analyzed for the concentrations of pro-inflammatory cytokines via multiplex suspension array.</s><s>(A) Interleukin (IL)-1β; (B) IL-6; (C) IL-9; (D) IL-12; (E) Interferon γ (IFN)γ; (F) Tumor necrosis factor α (TNFα).</s><s>Controls n = 42, IR patients n = 20.</s><s>IR-patients vs. controls Mann-Whitney U test, FH vs. corresponding SBM Wilcoxon test, p-values &lt; 0.05 are shown as numbers in the Figure.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Figure 3 .</head><label>3</label><figDesc><div><p><s>Figure 3. Regulatory cytokines are increased in FH/SBM of immunologically restricted patients.</s><s>Supernatants from FH and SBM of immunologically restricted patients (FH IR/SBM IR: dark grey) and controls (FH/SBM: light grey) were analyzed for the concentrations of regulatory cytokines via multiplex suspension array.</s><s>(A) IL-10; (B) IL-13.</s><s>Controls n = 42, IR patients n = 20.</s><s>IR-patients vs. controls Mann-Whitney U test, FH vs. corresponding SBM Wilcoxon test, p-values &lt; 0.05 are shown as numbers in the Figure.</s></p></div></figDesc><graphic coords="4,117.27,549.90,357.16,103.14" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>Figure 3 .</head><label>3</label><figDesc><div><p><s>Figure 3. Regulatory cytokines are increased in FH/SBM of immunologically restricted patients.</s><s>Supernatants from FH and SBM of immunologically restricted patients (FH IR/SBM IR: dark grey) and controls (FH/SBM: light grey) were analyzed for the concentrations of regulatory cytokines via multiplex suspension array.</s><s>(A) IL-10; (B) IL-13.</s><s>Controls n = 42, IR patients n = 20.</s><s>IR-patients vs. controls Mann-Whitney U test, FH vs. corresponding SBM Wilcoxon test, p-values &lt; 0.05 are shown as numbers in the Figure.</s></p></div></figDesc><graphic coords="4,122.19,539.10,357.16,103.14" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_8"><head>Figure 4 .</head><label>4</label><figDesc><div><p><s>Figure 4. Chemokines are up-regulated in FH/SBM of immunologically restricted patients.</s><s>Supernatants from FH and SBM of immunologically restricted patients (FH IR/SBM IR: dark grey) and controls (FH/SBM: light grey) were analyzed for the concentrations of chemokines via multiplex suspension array.</s><s>(A) Eotaxin/CCL11; (B) Interferon gamma-induced protein 10 (IP-10/CXCL10); (C) Macrophage inflammatory protein 1α (MIP-1α/CCL3); (D) Regulated on activation, normal T cell expressed and secreted (RANTES/CCL5).</s><s>Controls n = 42, IR patients n = 20.</s><s>IRpatients vs. controls Mann-Whitney U test, FH vs. corresponding SBM Wilcoxon test, p-values &lt; 0.05 are shown as numbers in the Figure.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_9"><head>Figure 4 .</head><label>4</label><figDesc><div><p><s>Figure 4. Chemokines are up-regulated in FH/SBM of immunologically restricted patients.</s><s>Supernatants from FH and SBM of immunologically restricted patients (FH IR/SBM IR: dark grey) and controls (FH/SBM: light grey) were analyzed for the concentrations of chemokines via multiplex suspension array.</s><s>(A) Eotaxin/CCL11; (B) Interferon gamma-induced protein 10 (IP-10/CXCL10); (C) Macrophage inflammatory protein 1α (MIP-1α/CCL3); (D) Regulated on activation, normal T cell expressed and secreted (RANTES/CCL5).</s><s>Controls n = 42, IR patients n = 20.</s><s>IR-patients vs. controls Mann-Whitney U test, FH vs. corresponding SBM Wilcoxon test, p-values &lt; 0.05 are shown as numbers in the Figure.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_10"><head>2. 5 .</head><label>5</label><figDesc><div><p><s>Factors Mediating Angiogenesis Were Found at Higher Concentrations within the Fracture Hematomas and the Surrounding Bone Marrow of Immunologically Restricted Patients When Compared to Controls</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_11"><head>Figure 5 .</head><label>5</label><figDesc><div><p><s>Figure 5. Angiogenic factors are highly secreted in FH/SBM of immunologically restricted patients.</s><s>Supernatants from FH and SBM of immunologically restricted patients (FH IR/SBM IR: dark grey) and controls (FH/SBM: light grey) were analyzed for the concentrations of angiogenic factors via multiplex suspension array.</s><s>(A) IL-8; (B) Macrophage migration inhibitory factor (MIF); (C) Platelet-derived growth factor (PDGF); (D) Granulocyte-colony stimulating factor (G-CSF).</s><s>Controls n = 42, IR patients n = 20.</s><s>IR-patients vs. controls Mann-Whitney U test, FH vs. corresponding SBM Wilcoxon test, p-values &lt; 0.05 are shown as numbers in the Figure.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_12"><head>Figure 5 .</head><label>5</label><figDesc><div><p><s>Figure 5. Angiogenic factors are highly secreted in FH/SBM of immunologically restricted patients.</s><s>Supernatants from FH and SBM of immunologically restricted patients (FH IR/SBM IR: dark grey) and controls (FH/SBM: light grey) were analyzed for the concentrations of angiogenic factors via multiplex suspension array.</s><s>(A) IL-8; (B) Macrophage migration inhibitory factor (MIF); (C) Platelet-derived growth factor (PDGF); (D) Granulocyte-colony stimulating factor (G-CSF).</s><s>Controls n = 42, IR patients n = 20.</s><s>IR-patients vs. controls Mann-Whitney U test, FH vs. corresponding SBM Wilcoxon test, p-values &lt; 0.05 are shown as numbers in the Figure.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_13"><head></head><label></label><figDesc><div><p><s>Criteria (at Present or in the Past) Patients with closed fractures Chronic infections (such as HIV, HBV, HCV, Tbc) Surgery within 72 h post injury AND one or more of the following conditions: Autoimmune diseases (n = 4) Osteoporosis (n = 6) Cancer (n = 4) Alcoholism (n = 4) Diabetes mellitus (n = 4) Chronic kidney disease (n = 3)</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_14"><head>Figure 6 .</head><label>6</label><figDesc><div><p><s>Figure 6.</s><s>Summary of differences in FH/SBM of immunologically restricted patients when compared to control patients, and the influence on initial bone healing (green arrows connect suggested main sources to cytokines released; red arrows connect released cytokines to their suggested main target mechanisms and mode of action-↑up-regulation/↓down-regulation-in bone healing).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_15"><head>Figure 6 .</head><label>6</label><figDesc><div><p><s>Figure 6.</s><s>Summary of differences in FH/SBM of immunologically restricted patients when compared to control patients, and the influence on initial bone healing (green arrows connect suggested main sources to cytokines released; red arrows connect released cytokines to their suggested main target mechanisms and mode of action-↑up-regulation/↓down-regulation-in bone healing).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Inclusion and exclusion criteria for patients defined as controls.</s></p></div></figDesc><table><row><cell>Inclusion Criteria</cell><cell>Exclusion Criteria (at Present or in the Past)</cell></row><row><cell></cell><cell>Autoimmune diseases</cell></row><row><cell></cell><cell>Immunosuppressive drugs (such as MTX, glucocorticoids,</cell></row><row><cell></cell><cell>cyclosporine, tacrolimus, sirolimus, biologics)</cell></row><row><cell>Patients with closed fractures</cell><cell>Osteoporosis</cell></row><row><cell>Surgery within 72 h post injury</cell><cell>Bone metabolism-relevant drugs (such as bisphosphonates,</cell></row><row><cell></cell><cell>glucocorticoids, denosumab, teriparatid)</cell></row><row><cell></cell><cell>Chronic infections (e.g., HIV, HBV, HCV, Tbc)</cell></row><row><cell></cell><cell>Cancer</cell></row><row><cell></cell><cell>Diabetes mellitus</cell></row><row><cell></cell><cell>Chronic kidney disease</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Patient characteristics.</s></p></div></figDesc><table><row><cell>Patients Groups</cell><cell>Years ± Standard Deviation</cell><cell>Age: Min-Max (years)</cell><cell>Male (%)</cell><cell>Female (%)</cell></row><row><cell>Healthy donors</cell><cell>53 ± 18.8</cell><cell>26-93</cell><cell>52.4</cell><cell>47.6</cell></row><row><cell>Immunologically restricted patients</cell><cell>70.1 ± 10.8</cell><cell>38-87</cell><cell>50</cell><cell>50</cell></row></table></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/3/583/s1.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments:</head><p><s>This study was supported by the German Research Foundation (DFG Bu1015/6-1).</s></p><p><s>Author Contributions: Paula Hoff, Timo Gaber, Georg Matziolis, Gerd-Rüdiger Burmester, Cindy Strehl, Carsten Perka, Georg N. Duda and Frank Buttgereit conceived and designed the experiments; Paula Hoff, Timo Gaber, Manuela Jakstadt, Cindy Strehl, Annemarie Lang, Eric Röhner and Gerhard Schmidmaier performed the experiments; Paula Hoff, Timo Gaber, Cindy Strehl, Annemarie Lang, Katharina Schmidt-Bleek and Dörte Huscher analyzed the data; Paula Hoff, Georg Matziolis, Gerd-Rüdiger Burmester, Eric Röhner, Gerhard Schmidmaier, Cindy Strehl, Carsten Perka, Georg N. Duda and Frank Buttgereit contributed reagents/materials/analysis tools; Paula Hoff, Timo Gaber, Holger Hoff and Frank Buttgereit wrote the paper.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflicts of Interest:</head><p><s>The authors declare no conflict of interest.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Ageing is associated with a decline in peripheral blood CD56bright NK cells</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Chidrawar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Nayak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Moss</surname></persName>
		</author>
		<idno type="DOI">10.1186/1742-4933-3-10</idno>
	</analytic>
	<monogr>
		<title level="j">Immun. Ageing</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">10</biblScope>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Postoperative host responses in elderly patients after gastrointestinal surgery</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ishikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nishioka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hanaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Miyauchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kashiwagi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kawasaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Miki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kagawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ioki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nakamura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatogastroenterology</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="730" to="735" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Are the immune responses different in middle-aged and young mice following bone fracture, tissue trauma and hemorrhage?</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Matsutani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Choudhry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Schwacha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Rue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">I</forename><surname>Bland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">H</forename><surname>Chaudry</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cyto.2004.03.005</idno>
	</analytic>
	<monogr>
		<title level="j">Cytokine</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="223" to="230" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Immunity, trauma and the elderly</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Smith</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.injury.2007.09.013</idno>
	</analytic>
	<monogr>
		<title level="j">Injury</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="1401" to="1404" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Immunity and age: Living in the past?</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Woodland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Blackman</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.it.2006.05.002</idno>
	</analytic>
	<monogr>
		<title level="j">Trends Immunol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="303" to="307" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">The convergence of fracture repair and stem cells: Interplay of genes, aging, environmental factors and disease</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hadjiargyrou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>O'keefe</surname></persName>
		</author>
		<idno type="DOI">10.1002/jbmr.2373</idno>
	</analytic>
	<monogr>
		<title level="j">J. Bone Miner Res</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="2307" to="2322" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Bone abnormalities in the surgical treatment of patients with rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Bogoch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Moran</surname></persName>
		</author>
		<idno type="DOI">10.1097/00003086-199909000-00003</idno>
	</analytic>
	<monogr>
		<title level="j">Clin. Orthop. Relat. Res</title>
		<imprint>
			<biblScope unit="volume">366</biblScope>
			<biblScope unit="page" from="8" to="21" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Busti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Hooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Amaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kazi</surname></persName>
		</author>
		<idno type="DOI">10.1592/phco.2005.25.11.1566</idno>
	</analytic>
	<monogr>
		<title level="j">Pharmacotherapy</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1566" to="1591" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Study on a nonhealing fracture from a patient with systemic lupus erythematosus and its pathogenetic mechanisms</title>
		<author>
			<persName><forename type="first">B</forename><surname>Dominiak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Oxberry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1080/01913120590912214</idno>
	</analytic>
	<monogr>
		<title level="j">Ultrastruct. Pathol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="107" to="120" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Understanding the role of immune regulation in wound healing</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Barbul</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0002-9610(03)00296-4</idno>
	</analytic>
	<monogr>
		<title level="j">Am. J. Surg</title>
		<imprint>
			<biblScope unit="volume">187</biblScope>
			<biblScope unit="page" from="11S" to="16S" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">The early fracture hematoma and its potential role in fracture healing</title>
		<author>
			<persName><forename type="first">P</forename><surname>Kolar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Schmidt-Bleek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Schell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gaber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Toben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schmidmaier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Perka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Buttgereit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Duda</surname></persName>
		</author>
		<idno type="DOI">10.1089/ten.teb.2009.0687</idno>
	</analytic>
	<monogr>
		<title level="j">Tissue. Eng. Part B Rev</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="427" to="434" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Immunological characterization of the early human fracture hematoma</title>
		<author>
			<persName><forename type="first">P</forename><surname>Hoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gaber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Schmidt-Bleek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Senturk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Tran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Blankenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lutkecosmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bredahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Schuler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Simon</surname></persName>
		</author>
		<idno type="DOI">10.1007/s12026-016-8868-9</idno>
	</analytic>
	<monogr>
		<title level="j">Immunol. Res</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="1195" to="1206" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Human early fracture hematoma is characterized by inflammation and hypoxia</title>
		<author>
			<persName><forename type="first">P</forename><surname>Kolar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gaber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Perka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Duda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Buttgereit</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11999-011-1865-3</idno>
	</analytic>
	<monogr>
		<title level="j">Clin. Orthop. Relat. Res</title>
		<imprint>
			<biblScope unit="volume">469</biblScope>
			<biblScope unit="page" from="3118" to="3126" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Immunologically restricted patients exhibit a pronounced inflammation and inadequate response to hypoxia in fracture hematomas</title>
		<author>
			<persName><forename type="first">P</forename><surname>Hoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gaber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Schmidt-Bleek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Senturk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Tran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Blankenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lutkecosmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bredahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Schuler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Simon</surname></persName>
		</author>
		<idno type="DOI">10.1007/s12026-011-8235-9</idno>
	</analytic>
	<monogr>
		<title level="j">Immunol. Res</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="116" to="122" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Regulation of bone development and extracellular matrix protein genes by RUNX2</title>
		<author>
			<persName><forename type="first">T</forename><surname>Komori</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00441-009-0832-8</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Tissue Res</title>
		<imprint>
			<biblScope unit="volume">339</biblScope>
			<biblScope unit="page" from="189" to="195" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Signaling networks in RUNX2-dependent bone development</title>
		<author>
			<persName><forename type="first">T</forename><surname>Komori</surname></persName>
		</author>
		<idno type="DOI">10.1002/jcb.22994</idno>
	</analytic>
	<monogr>
		<title level="j">J. Cell Biochem</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="750" to="755" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Transcriptional mechanisms in osteoblast differentiation and bone formation</title>
		<author>
			<persName><forename type="first">K</forename><surname>Nakashima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>De Crombrugghe</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0168-9525(03)00176-8</idno>
	</analytic>
	<monogr>
		<title level="j">Trends Genet</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="458" to="466" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Multiple roles for CCR2 during fracture healing</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Xing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Y</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Colnot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nakamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Miclau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Marcucio</surname></persName>
		</author>
		<idno type="DOI">10.1242/dmm.003186</idno>
	</analytic>
	<monogr>
		<title level="j">Dis. Model. Mech</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="451" to="458" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Tissue-specific contribution of macrophages to wound healing</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Minutti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Knipper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Allen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Zaiss</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.semcdb.2016.08.006</idno>
	</analytic>
	<monogr>
		<title level="j">Semin. Cell Dev. Biol</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="3" to="11" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b19">
	<monogr>
		<title level="m" type="main">Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ogilvie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Clark-Lewis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baggiolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Uguccioni</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood.V97.7.1920</idno>
		<imprint>
			<date type="published" when="1920">2001. 1920-1924</date>
			<biblScope unit="volume">97</biblScope>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Action of IL-1β during fracture healing</title>
		<author>
			<persName><forename type="first">J</forename><surname>Lange</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sapozhnikova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Miclau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Marcucio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Orthop. Res</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="778" to="784" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Interleukin-1β modulates endochondral ossification by human adult bone marrow stromal cells</title>
		<author>
			<persName><forename type="first">M</forename><surname>Mumme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Scotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Papadimitropoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Todorov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Hoffmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bocelli-Tyndall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jakob</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wendt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Barbero</surname></persName>
		</author>
		<idno type="DOI">10.22203/eCM.v024a16</idno>
	</analytic>
	<monogr>
		<title level="j">Eur. Cell. Mater</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="224" to="236" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">IL-1β inhibits human osteoblast migration</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Hengartner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fiedler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ignatius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Brenner</surname></persName>
		</author>
		<idno type="DOI">10.2119/molmed.2012.00058</idno>
	</analytic>
	<monogr>
		<title level="j">Mol. Med</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="36" to="42" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Review: Immune cells and mediators of inflammatory arthritis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Schett</surname></persName>
		</author>
		<idno type="DOI">10.1080/08916930701694717</idno>
	</analytic>
	<monogr>
		<title level="j">Autoimmunity</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="224" to="229" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Effect of interleukin-9 on clonogenic maturation and cell-cycle status of fetal and adult hematopoietic progenitors</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Holbrook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Ohls</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Schibler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Christensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="page" from="2129" to="2134" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">IL-12p40 impairs mesenchymal stem cell-mediated bone regeneration via CD4+ T cells</title>
		<author>
			<persName><forename type="first">J</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Geng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1038/cdd.2016.72</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Death Differ</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1941" to="1951" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Aging, inflammation, stem cells, and bone healing</title>
		<author>
			<persName><forename type="first">E</forename><surname>Gibon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Goodman</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13287-016-0300-9</idno>
	</analytic>
	<monogr>
		<title level="j">Stem Cell Res. Ther</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">44</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Modulation of osteoblastic cell efferocytosis by bone marrow macrophages</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Michalski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Koh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Weidner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Roca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">K</forename><surname>Mccauley</surname></persName>
		</author>
		<idno type="DOI">10.1002/jcb.25567</idno>
	</analytic>
	<monogr>
		<title level="j">J. Cell. Biochem</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="2697" to="2706" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Implications of mesenchymal stem cells in regenerative medicine</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kariminekoo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Movassaghpour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rahimzadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Talebi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Shamsasenjan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Akbarzadeh</surname></persName>
		</author>
		<idno type="DOI">10.3109/21691401.2015.1129620</idno>
	</analytic>
	<monogr>
		<title level="j">Artif. Cells Nanomed. Biotechnol</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="749" to="757" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells</title>
		<author>
			<persName><forename type="first">G</forename><surname>Zurawski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>De Vries</surname></persName>
		</author>
		<idno type="DOI">10.1016/0167-5699(94)90021-3</idno>
	</analytic>
	<monogr>
		<title level="j">Immunol. Today</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="19" to="26" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">IL-13 effector functions</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Wynn</surname></persName>
		</author>
		<idno type="DOI">10.1146/annurev.immunol.21.120601.141142</idno>
	</analytic>
	<monogr>
		<title level="j">Annu. Rev. Immunol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="425" to="456" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">MCP-1: Chemoattractant with a role beyond immunity: A review</title>
		<author>
			<persName><forename type="first">A</forename><surname>Yadav</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Saini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Arora</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cca.2010.07.006</idno>
	</analytic>
	<monogr>
		<title level="j">Clin. Chim. Acta</title>
		<imprint>
			<biblScope unit="volume">411</biblScope>
			<biblScope unit="page" from="1570" to="1579" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Macrophage inflammatory protein-1</title>
		<author>
			<persName><forename type="first">M</forename><surname>Maurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Von Stebut</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.biocel.2003.10.019</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Biochem. Cell Biol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="1882" to="1886" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Chemokines as regulators of T cell differentiation</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Luther</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Cyster</surname></persName>
		</author>
		<idno type="DOI">10.1038/84205</idno>
	</analytic>
	<monogr>
		<title level="j">Nat. Immunol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="102" to="107" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Wynn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Barron</surname></persName>
		</author>
		<author>
			<persName><surname>Macrophages</surname></persName>
		</author>
		<idno type="DOI">10.1055/s-0030-1255354</idno>
		<title level="m">Master regulators of inflammation and fibrosis. Semin. Liver Dis</title>
				<imprint>
			<date type="published" when="2010">2010</date>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="245" to="257" />
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Chemokines, chemokine receptors and allergy</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Kaplan</surname></persName>
		</author>
		<idno type="DOI">10.1159/000053777</idno>
	</analytic>
	<monogr>
		<title level="j">Int. Arch. Allergy Immunol</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="423" to="431" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease</title>
		<author>
			<persName><forename type="first">R</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ruan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Song</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12935-014-0132-6</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer Cell Int</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Functional expression of β-chemokine receptors in osteoblasts: role of regulated upon activation, normal T cell expressed and secreted (RANTES) in osteoblasts and regulation of its secretion by osteoblasts and osteoclasts</title>
		<author>
			<persName><forename type="first">S</forename><surname>Yano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mentaverri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kanuparthi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bandyopadhyay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rivera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Chattopadhyay</surname></persName>
		</author>
		<idno type="DOI">10.1210/en.2005-0065</idno>
	</analytic>
	<monogr>
		<title level="j">Endocrinology</title>
		<imprint>
			<biblScope unit="volume">146</biblScope>
			<biblScope unit="page" from="2324" to="2335" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Cellular energy metabolism in T-lymphocytes</title>
		<author>
			<persName><forename type="first">T</forename><surname>Gaber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Strehl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sawitzki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Buttgereit</surname></persName>
		</author>
		<idno type="DOI">10.3109/08830185.2014.956358</idno>
	</analytic>
	<monogr>
		<title level="j">Int. Rev. Immunol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="34" to="49" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Angiogenic factors in bone local environment</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Chim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tickner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Kuek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Erber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Xu</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cytogfr.2013.03.008</idno>
	</analytic>
	<monogr>
		<title level="j">Cytokine Growth Factor Rev</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="297" to="310" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">VEGF and bone cell signalling: An essential vessel for communication?</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Clarkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Gerstenfeld</surname></persName>
		</author>
		<idno type="DOI">10.1002/cbf.2911</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Biochem. Funct</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Influence of diabetic metabolic state on fracture healing in spontaneously diabetic rats</title>
		<author>
			<persName><forename type="first">N</forename><surname>Follak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kloting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Merk</surname></persName>
		</author>
		<idno type="DOI">10.1002/dmrr.537</idno>
	</analytic>
	<monogr>
		<title level="j">Diabetes Metab. Res. Rev</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="288" to="296" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Osteogenic protein-1 overcomes inhibition of fracture healing in the diabetic rat: A pilot study</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Kidder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Lew</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11999-008-0405-2</idno>
	</analytic>
	<monogr>
		<title level="j">Clin. Orthop. Relat. Res</title>
		<imprint>
			<biblScope unit="volume">467</biblScope>
			<biblScope unit="page" from="3249" to="3256" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Hip fracture in rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">B</forename><surname>Stromqvist</surname></persName>
		</author>
		<idno type="DOI">10.3109/17453678408992409</idno>
	</analytic>
	<monogr>
		<title level="j">Acta Orthop. Scand</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="624" to="628" />
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
	<note>PubMed</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Decreased platelet derived growth factor expression during fracture healing in diabetic animals</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Tyndall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Beam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zarro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>O'connor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Lin</surname></persName>
		</author>
		<idno type="DOI">10.1097/00003086-200303000-00043</idno>
	</analytic>
	<monogr>
		<title level="j">Clin. Orthop. Relat. Res</title>
		<imprint>
			<biblScope unit="volume">408</biblScope>
			<biblScope unit="page" from="319" to="330" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
